Insulet Presents Results of Omnipod 5 Automated Insulin Delivery System for T1D at ENDO 2021
- Insulet reported the results from the first pivotal trial of Omnipod 5 System in patients with T1D. The trial enrolls two groups that include 28 adults & adolescents aged 14-70yrs. and 112 children aged 6-13.9yrs.
- Results: In adults & adolescents and children- increase in time in range (70-180mg/dL) from 65% to 74% (additional 2.2hr/day) and 53% to 68% (additional 3.7hrs/day) with reduction of HbA1c from (7.16% to 6.78% and 7.67% to 6.99%)- decrease in mean glucose (161 to 154 mg/dL and 183 to 160 mg/dL) respectively
- The Omnipod 5 System received FDA’s BTD and is currently under review. Insulet is expected to launch Omnipod 5 in limited release in H1’21
Ref: Insulet | Image: National Investor Network
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at firstname.lastname@example.org